TD Cowen on Olema Pharmaceuticals (OLMA): 'Pala's Profile And Data Support Phase IIIs, Despite persevERA Disappointment'
TD Cowen analyst Tyler Van Buren reiterated a Buy rating on Olema Pharmaceuticals (NASDAQ: OLMA).The analyst comments "The failure of ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)